Akebia adds $50M deal with Vifor for exclusive US distribution deal for vadadustat
Akebia keeps stacking up the money deals for its closely-watched anemia drug.
In the latest deal announced after the market closed Monday, Vifor Pharma said it is buying a $50 million stake in Akebia $AKBA in exchange for an exclusive US distribution deal for their late-stage anemia drug vadadustat. Vifor is paying $14 a share in the deal to gain distribution rights to the drug for its Fresenius Medical Care dialysis clinics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.